GLP-1 medications like Ozempic, Wegovy and Mounjaro are now available through digital health companies. But Omada has chosen not to directly prescribe for diabetes or weight loss.
What are we doing instead? Amplifying the efforts of primary care providers (PCPs) in the time between visits with a comprehensive behavior change-backed program.
In the sixth part of Omada’s video blog series, Chief Medical Officer Carolyn Bradner Jasik, MD covers the reasoning behind this decision, and how Omada supports members in their weight loss journey.
